List of Excipients in Branded Drug BROMFENAC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sun Pharmaceutical Industries Inc	BROMFENAC	bromfenac	49708-755	ANHYDROUS CITRIC ACID
Sun Pharmaceutical Industries Inc	BROMFENAC	bromfenac	49708-755	BENZALKONIUM CHLORIDE
Sun Pharmaceutical Industries Inc	BROMFENAC	bromfenac	49708-755	BORIC ACID
Sun Pharmaceutical Industries Inc	BROMFENAC	bromfenac	49708-755	EDETATE DISODIUM
Sun Pharmaceutical Industries Inc	BROMFENAC	bromfenac	49708-755	POLOXAMER 407
Sun Pharmaceutical Industries Inc	BROMFENAC	bromfenac	49708-755	POLYCARBOPHIL

Generic Drugs Containing BROMFENAC

Company	Ingredient	NDC	Excipient
Alembic Pharmaceuticals Limited	bromfenac	46708-508	BORIC ACID
Alembic Pharmaceuticals Limited	bromfenac	46708-508	EDETATE DISODIUM
Alembic Pharmaceuticals Limited	bromfenac	46708-508	POLYSORBATE 80
Alembic Pharmaceuticals Limited	bromfenac	46708-508	POVIDONE K30
Alembic Pharmaceuticals Limited	bromfenac	46708-508	SODIUM BORATE
Alembic Pharmaceuticals Limited	bromfenac	46708-508	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in BROMFENAC?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
7	BENZALKONIUM CHLORIDE
10	BORIC ACID
10	EDETATE DISODIUM
1	POLOXAMER 407
1	POLYCARBOPHIL

Bromfenac Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: August 7, 2026

Bromfenac is a mature ophthalmic NSAID opportunity with limited molecule-level exclusivity but continuing formulation value. The commercial focus is bromfenac sodium ophthalmic solution, primarily 0.07% and 0.09% strengths used for postoperative ocular inflammation and pain. Generic competition has reduced the value of the original branded product, but differentiated excipient systems can still support premium products in preservative-free, multidose, low-irritation, and improved-retention segments.

The strongest opportunities are preservative-free delivery, reduced dosing frequency, container-closure differentiation, improved ocular comfort, and reformulation for patients who cannot tolerate sulfite-containing products. The main technical constraints are bromfenac solubility, pH-dependent stability, ocular irritation, oxidation control, and the need to maintain a clear, sterile ophthalmic solution.

What is bromfenac and how is it marketed?

Bromfenac is a topical ophthalmic nonsteroidal anti-inflammatory drug used after cataract surgery and other ocular procedures. The marketed active moiety is generally bromfenac sodium, including bromfenac sodium sesquihydrate in some product descriptions.

Product	Strength	Dosage form	Original sponsor or commercial owner	Primary use
Xibrom	0.09%	Ophthalmic solution	ISTA Pharmaceuticals	Postoperative ocular inflammation
Bromday	0.09%	Ophthalmic solution	ISTA Pharmaceuticals	Once-daily postoperative treatment
Prolensa	0.07%	Ophthalmic solution	Bausch + Lomb	Postoperative ocular inflammation and pain
Generic bromfenac sodium	0.07% and 0.09%	Ophthalmic solution	Multiple generic manufacturers	Equivalent postoperative treatment

Xibrom was approved in 2005, Bromday in 2010, and Prolensa in 2013. Bausch + Lomb acquired ISTA Pharmaceuticals in 2012, bringing the bromfenac franchise into the Bausch + Lomb ophthalmic portfolio (U.S. Food and Drug Administration [FDA], 2005, 2010, 2013; Bausch + Lomb, 2012).

Bromfenac competes with ketorolac, nepafenac, diclofenac, and fluorometholone-containing postoperative products. Its commercial positioning has historically relied on low dosing frequency, postoperative pain control, and a formulation designed for ocular tolerability.

What excipients are used in bromfenac ophthalmic products?

Commercial bromfenac solutions use a relatively conventional excipient system. The Prolensa label identifies boric acid, edetate disodium, povidone, polysorbate 80, sodium borate, sodium sulfite, sodium hydroxide, and water for injection as inactive ingredients (FDA, 2013).

Excipient	Functional role	Strategic significance
Boric acid	Buffering and tonicity contribution	Supports ocular-compatible pH control
Sodium borate	Buffering	Maintains formulation pH and buffering capacity
Sodium hydroxide	pH adjustment	Controls solubility and stability
Edetate disodium	Chelating agent	Binds trace metals that can catalyze oxidation
Sodium sulfite	Antioxidant or oxygen-scavenging support	Helps control oxidative degradation but may create tolerability concerns
Povidone	Wetting, viscosity, and retention aid	Can improve surface residence and comfort
Polysorbate 80	Solubilizer and surfactant	Supports uniformity and reduces interfacial adsorption
Water for injection	Vehicle	Sterile aqueous delivery medium

The excipient system is commercially important because bromfenac is delivered directly to the ocular surface. Small changes in pH, osmolality, surfactant concentration, viscosity, or preservative content can affect comfort, absorption, dosing adherence, and regulatory comparability.

Why is sodium sulfite strategically important?

Sodium sulfite can improve oxidative stability, but sulfite-containing ophthalmic products may be unattractive for patients with sulfite sensitivity or asthma-related concerns. The presence of sulfite creates a clear reformulation opportunity: maintain bromfenac stability through oxygen-reduced filling, improved container closure, chelation, optimized headspace, or alternative antioxidant systems.

A sulfite-free product would require a complete stability and ocular-tolerability package. Removing sulfite without replacing its stabilizing function could increase degradation, impurity formation, or shelf-life risk.

What excipient strategies could differentiate bromfenac?

Preservative-free bromfenac

Preservative-free bromfenac is the most direct commercial opportunity. A unit-dose product could remove chronic exposure to benzalkonium chloride, although the current bromfenac products identified above do not rely on benzalkonium chloride as the principal preservative system.

A preservative-free strategy could use:

• Unit-dose vials
• Blow-fill-seal packaging
• Sterile single-use ampoules
• Multidose preservative-free pump systems
• One-way valve containers
• Nitrogen-filled or low-oxygen packaging

The commercial trade-off is higher packaging cost and more complex manufacturing. Unit-dose packaging also increases material consumption and shipping volume. A multidose preservative-free system would offer better convenience but would require robust microbial ingress protection and container-closure validation.

Sulfite-free antioxidant systems

A sulfite-free formulation could combine:

• Metal chelation using edetate disodium or an alternative chelator
• Low-permeability container materials
• Reduced oxygen headspace
• Nitrogen purging
• Light-protective packaging
• Carefully selected antioxidant excipients
• Optimized pH and buffer concentration

Alternative antioxidants must be evaluated for ocular tolerability, extractables and leachables, compatibility with the drug substance, and regulatory precedent. A formulation that eliminates sulfite but requires an unusual antioxidant may gain limited commercial value if the new excipient creates its own safety or review burden.

Viscosity-enhanced formulations

Povidone is already used as a retention and comfort aid. Other viscosity modifiers, such as hydroxypropyl methylcellulose, carboxymethylcellulose, hyaluronic acid, or carbomer-type polymers, could increase ocular residence time.

The target is not maximum viscosity. Excess viscosity can cause blurred vision, transient discomfort, slower drop formation, and poor patient acceptance. A successful design would preserve drop accuracy while increasing precorneal residence and reducing drainage.

Potential claims could include:

• Reduced dosing frequency
• Improved postoperative exposure
• Lower volume loss after instillation
• Reduced need for repeated administration
• Improved patient-reported comfort

These claims would require clinical or pharmacokinetic support. A simple increase in viscosity is unlikely to create durable commercial differentiation without evidence of a meaningful clinical or adherence benefit.

Surfactant and solubilization optimization

Polysorbate 80 supports wetting and solubilization, but surfactants may contribute to ocular irritation, peroxide formation, or chemical instability. Alternatives include poloxamers, tyloxapol, cyclodextrins, or lower-surfactant systems.

A lower-surfactant formulation could be attractive if it improves comfort or reduces impurity risk. Cyclodextrin-based systems may improve apparent solubility, but they can increase formulation cost and complicate dose-volume and osmolality control.

In situ gelling systems

An in situ gel that remains fluid during administration and increases viscosity on the ocular surface could provide longer retention. Trigger mechanisms may include:

• Ion-responsive polymers
• Temperature-responsive polymers
• pH-responsive polymers
• Mucoadhesive polymer systems

This strategy has technical potential but faces a higher development burden. The product must remain easy to administer, avoid visual blurring, preserve sterility, and deliver a reproducible dose. A gel platform may also move the product away from a straightforward generic pathway.

What formulations are protected by bromfenac patents?

Bromfenac patent protection historically covered the active compound, ophthalmic compositions, dosing regimens, and improved postoperative treatment methods. The most commercially relevant protection was associated with branded ophthalmic formulations and once-daily or reduced-frequency treatment concepts.

The practical patent position is now divided into three categories:

Protection category	Current commercial relevance
Bromfenac compound patents	Largely expired or commercially exhausted
Original ophthalmic formulation patents	Primarily relevant to historical generic entry and litigation
New excipient, packaging, and dosing patents	Potentially available for new products if claims contain credible technical distinctions

The FDA Orange Book is the controlling source for current listed patents and regulatory exclusivity associated with approved drug products. Bromfenac products have undergone generic competition, indicating that the principal branded barriers did not prevent market entry indefinitely (FDA, Orange Book).

A new bromfenac product is unlikely to obtain meaningful protection from broad claims covering “bromfenac ophthalmic solution.” Stronger claim opportunities would focus on specific, reproducible technical features, such as:

• A sulfite-free composition with defined impurity limits
• A specified pH and buffer ratio linked to stability
• A preservative-free multidose container system
• A defined viscosity range linked to ocular residence
• A low-oxygen packaging configuration
• A specific particle or impurity control profile
• A validated once-daily regimen supported by clinical data
• A combination of bromfenac with another postoperative agent

Patentability will depend on unexpected stability, tolerability, bioavailability, dosing, or adherence results. Routine substitution of one buffer, surfactant, or viscosity agent for another is vulnerable to obviousness challenges.

When does bromfenac lose exclusivity?

Bromfenac’s original U.S. small-molecule and product-related exclusivity has largely expired. Xibrom, Bromday, and Prolensa were approved between 2005 and 2013, and generic bromfenac products are now marketed in the United States.

Milestone	Approximate timing
Xibrom approval	2005
Bromday approval	2010
Prolensa approval	2013
Generic bromfenac entry	Began after applicable patent and regulatory barriers were overcome
Current market position	Generic and branded products coexist

Bromfenac does not have biosimilar risk because it is a chemically synthesized small molecule, not a biologic. The relevant competitive risks are abbreviated new drug applications, formulation-specific challenges, authorized generic competition, and follow-on ophthalmic products.

Which companies are challenging bromfenac exclusivity?

The generic market includes multiple manufacturers and label holders for bromfenac sodium ophthalmic solution. The competitive field has included companies such as Akorn, Amneal, Apotex, Lupin, Rising Pharma, Teva, and other generic suppliers, depending on product strength, approval status, and market period.

Historical Paragraph IV challenges affected branded bromfenac products, particularly where generic applicants sought approval before expiry of listed formulation or method-of-use patents. The commercial effect of those challenges was to accelerate settlement negotiations, patent litigation, or later generic entry.

For a current transaction or launch decision, the relevant information is the FDA’s active product listings, Orange Book patent entries, approved ANDA ownership, and any current district court or Federal Circuit proceedings. Historical Paragraph IV activity is less important than whether any enforceable patent remains listed against the specific strength and dosage form.

What patent litigation affects bromfenac?

Bromfenac litigation has generally involved the standard branded-generic disputes for ophthalmic products:

• Whether the generic formulation falls within a listed composition claim
• Whether a dosing regimen is protected by a method-of-use patent
• Whether a generic label induces infringement
• Whether a formulation patent is invalid for obviousness or lack of written description
• Whether a patent applicant’s Paragraph IV certification creates a justiciable infringement dispute

The most durable litigation exposure for a new product would come from later-issued formulation patents rather than expired compound patents. A company developing a differentiated bromfenac formulation should conduct freedom-to-operate analysis across:

1. Composition claims
2. pH and buffer ranges
3. Antioxidant and chelator combinations
4. Viscosity and polymer systems
5. Container-closure and multidose delivery
6. Dosing frequency and postoperative indications
7. Combination therapy claims

How strong is the bromfenac patent estate?

The legacy bromfenac estate is commercially weak for an undifferentiated product because generic products already compete in the market. The opportunity is stronger for a technically distinct product with new formulation and delivery claims.

Estate component	Strength for a new entrant
Active ingredient	Low
Conventional aqueous solution	Low
Standard buffer system	Low to moderate
Sulfite-free stability platform	Moderate, if supported by unexpected data
Preservative-free multidose container	Moderate to strong
In situ gel or mucoadhesive delivery	Moderate
New combination product	Moderate to strong
Novel dosing regimen	Moderate, subject to clinical evidence
Manufacturing process with impurity control	Moderate, but difficult to enforce against competitors

Trade-secret protection may be more valuable than patents for manufacturing controls, oxygen management, filling parameters, impurity specifications, and container preparation. These features can be difficult for competitors to detect from the finished product.

What FDA regulatory pathways apply to bromfenac reformulations?

A conventional bromfenac sodium ophthalmic solution may qualify for an ANDA if it demonstrates pharmaceutical equivalence and bioequivalence to a reference-listed drug. A materially different formulation may require a 505(b)(2) application.

Product strategy	Likely pathway
Same strength, dosage form, route, and comparable excipients	ANDA
New excipient, preservative-free system, or delivery device with clinical differentiation	505(b)(2)
New combination with another active ingredient	505(b)(2) or new drug application
New postoperative indication or dosing regimen	505(b)(2) or supplemental application
Compounded or pharmacy-specific preparation	Not a commercial approval pathway

A 505(b)(2) strategy can support differentiated labeling and formulation claims but usually requires greater investment in safety, stability, device, and clinical studies. For topical ophthalmic products, comparative clinical endpoint studies may be necessary where in vitro or pharmacokinetic methods cannot establish equivalence.

Critical regulatory development areas include:

• Sterility assurance
• Particulate matter
• Antimicrobial effectiveness where applicable
• Container-closure integrity
• Extractables and leachables
• Ocular irritation
• Drop size and delivered dose
• In-use stability
• Preservative-free multidose performance
• Photostability and oxidative stability

What commercial opportunities exist for bromfenac?

Premium postoperative ophthalmic product

A sulfite-free, preservative-free bromfenac product could target surgeons and patients who value comfort, lower excipient exposure, or simplified postoperative regimens. Premium pricing would require evidence that the product improves tolerability, adherence, or clinical workflow.

Combination therapy

Bromfenac could be combined with a corticosteroid, antibiotic, or another anti-inflammatory agent. Combination products could reduce the number of postoperative bottles and simplify prescribing.

The barriers are substantial. Fixed-dose combinations require compatibility data, dose justification, stability work, and a clear clinical rationale. A combination may also compete with established branded combinations and surgeon-specific prescribing protocols.

Device-enabled multidose delivery

A preservative-free multidose system could create a differentiated product without changing the active ingredient. The value proposition would be strongest in ambulatory surgery centers, ophthalmology practices, and patients requiring repeated postoperative treatment.

The principal risks are device cost, dose uniformity, microbial protection, supply-chain complexity, and the need to establish device-drug compatibility.

Emerging-market and regional licensing

Bromfenac has lower development risk than an unapproved ophthalmic molecule. Regional partners could commercialize:

• Generic 0.07% and 0.09% solutions
• Preservative-free unit-dose products
• Hospital and surgical-center packs
• Combination products
• Private-label ophthalmic products

Geographic patent exposure is uneven. U.S. compound and product patents may be exhausted, while some jurisdictions may retain formulation, process, or regulatory exclusivity. A licensing review should distinguish patent status from product-registration status because local market access may depend more on regulatory dossiers, manufacturing approvals, and tender contracts than on active patents.

What manufacturing and intellectual-property barriers exist?

Bromfenac solution manufacturing is not conceptually complex, but ophthalmic quality requirements create execution barriers. The highest-risk steps include:

• Maintaining bromfenac concentration during compounding and filling
• Controlling pH drift
• Preventing oxidative degradation
• Managing polysorbate-related impurities
• Achieving sterile filtration or validated aseptic processing
• Controlling low-level particulates
• Ensuring drop-size consistency
• Validating multidose container performance

A new entrant must also establish supply security for sterile-grade excipients, ophthalmic packaging, and specialized filling capacity. Preservative-free multidose packaging can create a stronger operational barrier than the bromfenac formulation itself.

How does bromfenac compare with ketorolac and nepafenac?

Attribute	Bromfenac	Ketorolac	Nepafenac
Class	NSAID	NSAID	NSAID prodrug
Common postoperative strength	0.07% or 0.09%	0.4% or 0.5%	0.1% or higher-strength products
Typical positioning	Reduced-frequency dosing and pain control	Established generic, broad use	Prodrug conversion and branded formulation differentiation
Biosimilar risk	None	None	None
Generic pressure	High	High	High, with branded differentiation
Excipient opportunity	Preservative-free, sulfite-free, retention systems	Similar, but more crowded	Solubility, suspension or solution, and comfort systems
Patent opportunity	New delivery and excipient claims	Reformulation and device claims	Prodrug, formulation, and delivery claims

Bromfenac’s commercial advantage is most credible when tied to dosing convenience or tolerability. A product that is merely another standard multidose solution will face price competition from established generics.

What revenue exposure does bromfenac create?

Revenue exposure depends on the product model:

Model	Revenue profile	Margin outlook
Commodity generic solution	Volume-driven	Low
Authorized generic	Moderate volume	Low to moderate
Branded preservative-free product	Lower volume	Moderate to high
Device-enabled multidose product	Moderate volume	High if adoption is established
Combination product	Potentially high	Moderate to high, with greater development cost
Regional licensing	Milestone and royalty income	Depends on territory and partner

The largest commercial risk is rapid price erosion after generic entry. The largest upside is a differentiated product that obtains a separate prescription position through a 505(b)(2) pathway, formulation patent, device claim, or clinical labeling advantage.

Key Takeaways

• Bromfenac is a mature ophthalmic NSAID with active generic competition and limited remaining value in the unmodified molecule.
• The principal opportunity is formulation differentiation, not compound-level exclusivity.
• Preservative-free delivery, sulfite-free stability, multidose packaging, improved ocular retention, and combination therapy are the leading strategies.
• Sodium sulfite, polysorbate 80, pH control, chelation, and viscosity are central formulation variables.
• A conventional bromfenac solution may fit an ANDA pathway; materially differentiated products may require 505(b)(2) development.
• New patent value is most likely in specific excipient combinations, container systems, impurity controls, and clinically supported dosing regimens.
• Bromfenac has no biosimilar risk because it is a small molecule.
• Manufacturing know-how, sterile filling, oxygen control, and preservative-free packaging may provide stronger practical barriers than broad formulation patents.
• A premium product needs evidence of improved comfort, adherence, safety, or dosing convenience to avoid generic price competition.

FAQs

Is bromfenac sodium ophthalmic solution still commercially attractive?

Yes, but mainly as a differentiated product. Commodity bromfenac has limited margin potential because generic competition is established.

Can a preservative-free bromfenac product receive new patent protection?

Yes. Patentable subject matter could include a specific preservative-free composition, multidose container, stability profile, or manufacturing process. Broad claims to bromfenac eye drops would be vulnerable.

Is sulfite-free bromfenac a realistic reformulation opportunity?

Yes. The formulation must replace or compensate for sulfite-related oxidative protection through packaging, oxygen control, chelation, pH optimization, or a validated alternative antioxidant system.

Would a bromfenac combination product require new clinical studies?

Often, yes. The required evidence depends on the combination, doses, proposed labeling, and the extent to which existing data can support the 505(b)(2) application.

What is the most defensible bromfenac commercial strategy?

A preservative-free or sulfite-free product using a differentiated delivery system and supported by tolerability, stability, and adherence data offers the strongest defensible position.

References

1. Bausch + Lomb. (2012). Bausch + Lomb completes acquisition of ISTA Pharmaceuticals.
2. U.S. Food and Drug Administration. (2005). Xibrom (bromfenac ophthalmic solution) prescribing information.
3. U.S. Food and Drug Administration. (2010). Bromday (bromfenac ophthalmic solution) prescribing information.
4. U.S. Food and Drug Administration. (2013). Prolensa (bromfenac sodium ophthalmic solution) prescribing information.
5. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
6. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.